Current Edition

Upcoming Events

Advertisement

news

Q1 earnings preview: Novo, Celgene still to come

It hasn't been the prettiest first quarter for drugmakers. Sanofi's revenue fell, as did confidence in one of the company's key growth drivers. Allergan discussed a s...
Continue Reading →
news

For Expensive New Drugs, Biopharma Should Make Money-Back Guarantees Mandatory

In a recent paper on “Value-Based Pricing for Drugs”, authors Anna Kaltenboeck and Peter B. Bach of the Memorial Sloan Kettering Cancer Center discuss the high cost o...
Continue Reading →
news

ExpreS2ion’s U.S. partner Integrated BioTherapeutics launches first ExpreS2-based research product

ExpreS2ion Biotechnologies ApS (“ExpreS2ion”) announces that its U.S.-based partner and licensee Integrated BioTherapeutics (“IBT”) has initiated sales and marketin...
Continue Reading →
news

Saunders: All options remain on the table for Allergan

Brief: Allergan CEO Brent Saunders said Monday the Irish pharma is considering a wide range of business options, including further divestitures or a split of the ...
Continue Reading →
news

United Therapeutics nabs competing PAH drug with $216M SteadyMed buy

Brief: United Therapeutics announced Monday morning that it will acquire competitor SteadyMed for $4.46 per share in cash upfront and another $2.63 per share in c...
Continue Reading →
news

Sparks sells regulatory fast pass to Jazz for $110M

Brief: Spark Therapeutics has sold a priority review voucher (PRV) to Jazz Pharmaceuticals for $110 million, according to a Monday disclosure. While details wer...
Continue Reading →
news

Wickham Laboratories to present at Cleanroom Technology Conference 2018

Wickham Laboratories CEO, Dr John McKenzie, will be presenting at the Cleanroom Technology Conference on the 16th May at 2:30PM, at the National Conference Centre in ...
Continue Reading →
news

Pfizer Receives CRL for Biosimilar to Roche’s Herceptin

On April 23, 2018, Pfizer announced that it received a complete response letter (CRL) from FDA in response to the biologics license application (BLA) for the company’...
Continue Reading →
news

VIVUS Restructures Debt and Gains Access to New Capital

Athyrium Capital Management partners with VIVUS to support next growth phase New capital to be used to facilitate the acquisition of PANCREAZE® (pancrelipase) VIVUS, ...
Continue Reading →
news

Chinese biopharma firm to create 400 jobs in Dundalk

WuXi Biologics will invest €325m in company’s first site outside of China Taoiseach Leo Varadkar at the announcement of...
Continue Reading →